Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of MG-S-2525 in Healthy Volunteers
NCT03650075Phase 1Completed
- Sponsor
- Metagone Biotech Inc.
- Start
- Feb 2019
- Primary completion
- Dec 2019
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MG-S-2525 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Metagone Biotech Inc. Primary endpoints: Maximum Tolerated Dose at 15 days, Dose Limiting Toxicity at 15 days and 2 more. Started Feb 2019; status: completed.
02
Drugs
MG-S-2525
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03650075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03650075.